Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $0.3530 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The firm had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $1.01 million. On average, analysts expect Eyepoint Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $13.34 on Monday. Eyepoint Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $19.11. The firm has a market cap of $1.12 billion, a P/E ratio of -4.22 and a beta of 1.76. The company has a 50 day moving average of $14.51 and a 200 day moving average of $14.58.

Analysts Set New Price Targets

A number of research firms have commented on EYPT. Citigroup lifted their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Chardan Capital increased their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Finally, HC Wainwright boosted their target price on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $32.20.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in EYPT. Russell Investments Group Ltd. purchased a new position in shares of Eyepoint Pharmaceuticals in the third quarter worth approximately $76,000. Tower Research Capital LLC TRC increased its holdings in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after buying an additional 5,967 shares during the last quarter. California State Teachers Retirement System increased its holdings in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after buying an additional 794 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in Eyepoint Pharmaceuticals in the fourth quarter worth approximately $98,000. Finally, Raymond James Financial Inc. raised its position in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.